Related Experiment Video
Updated: Jul 23, 2026

Sagittal Plane Kinematic Gait Analysis in C57BL/6 Mice Subjected to MOG35-55 Induced Experimental Autoimmune Encephalomyelitis
Published on: November 4, 2017
A Simple Score (MOG-AR) to Identify Individuals at High Risk of Relapse After MOGAD Attack
Yun Xu1, Huaxing Meng1, Moli Fan1
1From the Department of Neurology (Y.X., L.Y., J.S., Y.Y., Y.W., H.C., H.W., T.S., F.-D.S., X.Z., D.-C.T.), China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University; Department of Neurology (H.M.), First Hospital of Shanxi Medical University, Taiyuan; Department of Neurology (M.F., C.-S.Y., F.-D.S.), Tianjin Neurological Institute, Tianjin Medical University General Hospital; and Department of Neurology (J.F.), The First Affiliated Hospital of Chongqing Medical University, China.
Background And Objectives:
To identify predictors for relapse in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and to develop and validate a simple risk score for predicting relapse.
Methods:
In China National Registry of Neuro-Inflammatory Diseases (CNRID), we identified patients with MOGAD from March 2023 and followed up prospectively to September 2023. The primary endpoint was MOGAD relapse, confirmed by an independent panel. Patients were randomly divided into model development (75%) and internal validation (25%) cohorts. Prediction models were constructed and internally validated using Andersen-Gill models. Nomogram and relapse risk score were generated based on the final prediction models.
Results:
A total of 188 patients (comprising 612 treatment episodes) were included in cohorts. Female (HR: 0.687, 95% CI 0.524-0.899, p = 0.006), onset age 45 years or older (HR: 1.621, 95% CI 1.242-2.116, p < 0.001), immunosuppressive therapy (HR: 0.338, 95% CI 0.239-0.479, p < 0.001), oral corticosteroids >3 months (HR 0.449, 95% CI 0.326-0.620, p < 0.001), and onset phenotype (p < 0.001) were identified as factors associated with MOGAD relapse. A predictive score, termed MOG-AR (Immunosuppressive therapy, oral Corticosteroids, Onset Age, Sex, Attack phenotype), derived in prediction model, demonstrated strong predictive ability for MOGAD relapse. MOG-AR score of 13-16 indicates a higher risk of relapse (HR: 3.285, 95% CI 1.473-7.327, p = 0.004).
Discussion:
The risk of MOGAD relapse seems to be predictable. Further validation of MOG-AR score developed from this cohort to determine appropriate treatment and monitoring frequency is warranted.
Trial Registration Information:
CNRID, NCT05154370, registered December 13, 2021, first enrolled December 15, 2021.
Insights
Predicting relapse in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is possible. A new MOG-AR score identifies patients at higher risk for MOGAD relapse, aiding treatment decisions.
Area of Science:
- Neuroimmunology
- Neurology
- Clinical Prediction Models
Background:
- Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a rare autoimmune disorder affecting the central nervous system.
- Predicting relapse is crucial for managing MOGAD and optimizing patient outcomes.
- Identifying reliable predictors of relapse can guide therapeutic strategies and monitoring protocols.
Purpose of the Study:
- To identify predictors of relapse in patients diagnosed with MOGAD.
- To develop and validate a simple risk score for predicting MOGAD relapse.
- To inform clinical management and personalize treatment approaches for MOGAD patients.
Main Methods:
- Prospective cohort study of 188 MOGAD patients from the China National Registry of Neuro-Inflammatory Diseases (CNRID).
- Patients were randomly assigned to model development (75%) and internal validation (25%) cohorts.
- Andersen-Gill models were used to construct and validate prediction models, generating a nomogram and relapse risk score (MOG-AR).
Main Results:
- Key predictors for MOGAD relapse included female sex, age 45 years or older, immunosuppressive therapy, prolonged oral corticosteroid use (>3 months), and onset phenotype.
- The developed MOG-AR score, incorporating these factors, demonstrated strong predictive ability for MOGAD relapse.
- A MOG-AR score of 13-16 indicated a significantly higher risk of relapse (HR: 3.285).
Conclusions:
- MOGAD relapse risk is predictable using clinical and treatment-related factors.
- The MOG-AR score shows promise for identifying patients at high risk of relapse.
- Further external validation of the MOG-AR score is warranted to guide treatment and monitoring frequency.
Related Concept Videos
Multiple Comparison Tests
It would be easy to compare two samples using a significance alpha level of 0.05. In other words, there is only one sample pair to be compared. However, it would be difficult to identify a significantly different sample if the number...
Methods of Documentation II: POMR
Relative Risk
Design Example: Analyzing Capacity Contours for Flood Risk Assessment
Hazard Rate
Hazard Ratio
For example, in a clinical trial evaluating a...

